Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spectral AIMDAI +1.85%6 Debt-to-Equity is -1.13 as of Mar. 2026. GuruFocus rates MDAI with a GF Score™ of 6/100 and a GF Value™ of $0.90 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 706 Medical Devices & Instruments companies, Spectral AI ranks worse than 141642.92% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Spectral AI's Debt-to-Equity or its related term are showing as below:
MDAI'
s Debt-to-Equity Range Over the Past 10 Years
Min: -6 Med: -1.09 Max: 1.15
Current: -1.13
During the past 5 years, the highest Debt-to-Equity Ratio of Spectral AI was 1.15. The lowest was -6.00. And the median was -1.09.
MDAI's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.23
vs MDAI: -1.13
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Spectral AI Debt-to-Equity Related Terms
Spectral AI Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Spectral AI's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDAI vs ECOR, COCH, SNWV: Debt-to-Equity Comparison
For the Medical Devices subindustry, Spectral AI's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spectral AI Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Spectral AI's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Spectral AI's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spectral AI (MDAI) has a Debt-to-Equity of -1.13 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Spectral AI and its competitors. According to the industry distribution chart, Spectral AI ranks #999999 out of 706 companies in the Medical Devices & Instruments industry.
Is Spectral AI's Debt-to-Equity too high?
Spectral AI's current Debt-to-Equity is -1.13. Based on the distribution chart, Spectral AI ranks #999999 out of 706 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Spectral AI has a GF Score™ of 6/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spectral AI's Debt-to-Equity compare to ECOR and COCH?
According to the Medical Devices & Instruments industry distribution chart, Spectral AI ranks #999999 out of 706 companies for Debt-to-Equity. This places Spectral AI in the lower half of its industry. The industry median Debt-to-Equity is 0.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Spectral AI and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spectral AI's current Debt-to-Equity is -1.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spectral AI stock overvalued right now?
Based on GuruFocus' analysis, Spectral AI (MDAI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.90, compared to a current price of $1.66 — trading 83.9% above its estimated fair value. The current Debt-to-Equity is -1.13. Spectral AI's overall GF Score™ is 6/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Spectral AI (MDAI), the current Debt-to-Equity is -1.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spectral AI (MDAI) Overvalued in 2026?
Based on GuruFocus' analysis, Spectral AI stock appears to be overvalued.
The current stock price of $1.66 is trading 83.9% above its estimated GF Value™ of $0.90.
GuruFocus considers Spectral AI to be Significantly Overvalued.
Key valuation signals for MDAI:
Debt-to-Equity: -1.13
GF Value™: $0.90 vs. price of $1.66 (83.9% above fair value)
No single metric tells the full story. See the MDAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spectral AI Inc is an AI company focused on predictive medical diagnostics. Its DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wound's capacity to heal or not-heal by a specified time point in the future. The company focuses on the burn indication which is supported by the BARDA PBS contract.
6GF Score
Get the complete analysis for MDAI
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDAI has been successfully added to your 
